HDS treatment schema. G-CSF indicates granulocyte colony-stimulating factor; ×, administration; ¬, apheresis; ↑, reinfusion. ^*If quantitatively adequate (ie, ≥10 × 10⁶/kg) and PCR-negative, the post–cyclophosphamide leukapheresed cells (apheresis 1) were used for all 3 subsequent reinfusions. Alternatively, 2 × 10⁶/kg of them were reinfused after cytarabine, while the postcytarabine harvested cells (apheresis 2) were used for reinfusions 2 and 3, respectively. †Cycles 2, 3, and 4 were started as soon as both hematologic and nonhematologic toxicities from prior the cycle had disappeared (usually on day 21 after cycle 1 and 2, and on day 28 after cycle 3).